USA flag logo/image

An Official Website of the United States Government

HTLV-III/LAV FOR POTENTIAL USE AS A RECOMBINANT SUBUNIT VACCINE

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
4791
Program Year/Program:
1986 / SBIR
Agency Tracking Number:
4791
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
NEUGENESIS CORPORATION
NEUGENESIS CORPORATION 871 INDUSTRIAL RD, STE J SAN CARLOS, CA 94070
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1986
Title: HTLV-III/LAV FOR POTENTIAL USE AS A RECOMBINANT SUBUNIT VACCINE
Agency: HHS
Contract: N/A
Award Amount: $50,000.00
 

Abstract:

HTLV-III/LAV IS A RECENTLY DESCRIBED HUMAN RETROVIRUS LINKEDBOTH MOLECULAR- AND SEROEPIDEMIOLOGICALLY TO THE CURRENT EPIDEMIC OF AIDS. IT SHOULD BE POSSIBLE NOT ONLY TO INTERFERE WITH VIRAL PROPOGATION IN A CHEMOTHERAPEUTIC MANNER BUT ALSO TO EFFECT IMMUNOPROPHYLAXIS IN THE AT-RISK POPULATION, AS THE SYNDROME HAS AN INFECTIOUS ETIOLOGY. THEAIM OF THIS PROJECT IS TO IDENTIFY VIRALLY ENCODED ANTIGENICDETERMINANTS THAT ARE PRODUCED IN A RECOMBINANT DNA EXPRESSION VECTOR BY IMMUNOSCREENING PROTOCOLS. WELL- CHARACTERIZED RECOMBINANT HTLV-III ANTIGENS MAY SERVE AS SEROTYPIC MARKERS OF DISEASE AND WILL BE ASSAYED FOR THEIR EFFECT IN BLOCKING IN VITRO MEASURES OF NEUTRALIZATION. A RECOMBINANT EPITOPE EFFECTIVE IN THE LATTER ASSAY WOULD BE APRIME CANDIDATE FOR A RECOMBINANT SUBUNIT VACCINE.

Principal Investigator:

Gregory r reyes
PRINCIPAL INVESTIGATOR
4155941600

Business Contact:

Small Business Information at Submission:

Gene Labs Inc
871 Industrial Road Building J San Carlos, CA 94070

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No